GSK Licenses Phase II Compounds from Exelixis

By Business Review Editor

Pharma Deals Review: Vol 2002 Issue 30 (Table of Contents)

Published: 2 Nov-2002

DOI: 10.3833/pdr.v2002.i30.976     ISSN: 1756-7874

Section: Licensing



Exelixis signed a major licensing deal with GlaxoSmithKline for a series of Phase II compounds for the treatment of cardiovascular diseases, cancers and inflammatory diseases...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details